REG - Cambridge Cognition - Electronic Clinical Outcomes Assessment Contract

Cambridge Cognition HoldingsAnnouncement

16/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211216:nRSP8075Va&default-theme=true

RNS Number : 8075V  Cambridge Cognition Holdings PLC  16 December 2021

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Electronic Clinical Outcomes Assessment contract win worth over £500,000

 

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it has
won a contract worth over £500,000 to provide electronic clinical outcome
assessments ("eCOA") to support a major pharmaceutical client (the "Client")
in delivering a Phase II paediatric study over several years. This is the
second eCOA contract Cambridge Cognition has secured with the Client in just
over a year. The first was of a similar value and referenced in the Company's
trading update on 30 June 2020.

 

To support the Client in establishing the safety and efficacy of a new drug,
the Company will collect patients' and parents' experiences with electronic
questionnaires, scales and diaries. This data will be collected both in
clinics on iPads and at home on smartphones using Cambridge Cognition's eCOA
system. Cambridge Cognition's experienced study management team will work
closely with the Client to ensure successful use of the software and
devices.

 

The provision of eCOA for clinical trials is a sizeable growth market, valued
at over US$1bn per annum and growing at 15% according to market research
reports(1).  Cambridge Cognition provides eCOA solutions primarily for
clinical trials for central nervous systems disorders, such as Alzheimer's
disease, although can also support other conditions.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"At Cambridge Cognition, we pride ourselves on our customer service and I am
pleased to see this recognised with repeat custom from a major pharmaceutical
client.  In addition, it is a success for our commercialisation strategy as
it again shows that our eCOA solution can be a standalone product, as well as
an upsell with cognitive assessments for clinical trials."

 

1. Grand View Research, Electronic Clinical Outcome Assessment Solutions
Market, 2018

 

For further information, contact:

 

 Cambridge Cognition Holdings PLC                       Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                 press@camcog.com (mailto:press@camcog.com)

 Sally Jennings, Head of Marketing and Communications
 finnCap Ltd (NOMAD and Joint Broker)                   Tel: 020 7220 0500

 Geoff Nash / Simon Hicks                               (Corporate Finance)

 Alice Lane / Charlotte Sutcliffe                       (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)                 Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                 Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTMZMMZRKVGMZM